Welcome to the 4th Annual Gene Therapy Analytical Development Summit
Uniting the leading minds in Analytical Development, CMC, Regulatory, QC, and Process Development, the 4th Annual Gene Analytical Development Summit is the industry’s only meeting focused on tackling the greatest analytical development challenges in the context of gene therapy drug development.
Hear from the likes of AstraZeneca, Sanofi, Novartis, bluebird bio, Biogen, Johnson & Johnson and more across a preconference workshop day, 4 tracks of in-depth case studies, interactive panel discussions, dedicated Q+A time, a post conference focus day and highly appraised networking opportunities to meet and learn from the leaders of this pioneering field.
Join your peers in person to:
Evaluate the current regulatory expectations for product-release testing to ensure your gene therapy meets the current criteria around quality, purity, and strength
Discover the new and improved genome quantification methods for late-stage clinical development to accurately quantify transgene expression and inform clinical dosing decisions
Determine the advantages of orthogonal methods (AUC, SEC-MALS), for the accurate assessment of empty: full capsids to guarantee efficacy and safety of AAV vector products
Explore the movement towards automation of analytics to reduce resource burden and improve sensitivity and efficiency of analytical data generation
Uncover the analytical tools being leveraged for non AAV gene therapies to navigate the nuanced complexities when characterizing gRNAs and ribonucleoproteins for CRISPR applications
Assess how analytical comparability strategies can be leveraged to strengthen process development
Enhance your understanding of your genome integrity and identity with talks exploring next-generation sequencing
Don’t miss the opportunity to network with 300+ analytical experts to overcome your analytical challenges encountered in every stage of the gene therapy development life cycle.
Access the official event guide to learn more.
“A great conference for everyone in the Analytical Development for gene therapy field." Novartis